CEFOXITIN

Bowel Cancer

EgymedicalpediaSmall moleculeN/AActive

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 95/ 100

Competitive context

2 Active assets in the Bowel Cancer cohort.

Asset / Sponsor	Phase	Rating
Artesunate Metanoic Health Ltd.	Phase 2	CCC
Recombinant Human Interleukin-2 Yi Miao	Phase 1	CC
her2bi-armed activated t cells Yi Miao	Phase 1	C
SODIUM PHOSPHATE Egymedicalpedia	N/A	D
Rifaximin National and Kapodistrian University of Athens	N/A	D

Same molecule, other indications

CEFOXITIN is also rated in:

pancreas disorderDormant

B

Indicative ·

62 / 100

malignant pancreatic neoplasmDormant

B

Indicative ·

57 / 100

pulmonary non-tuberculous mycobacterial infectionDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.